about
Potentially inappropriate medication use in older patients in Swiss managed care plans: prevalence, determinants and association with hospitalizationIdentifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications.Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data.Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09).Estimating the prevalence of comorbid conditions and their effect on health care costs in patients with diabetes mellitus in Switzerland.The relationship between functional health literacy and the use of the health system by diabetics in Switzerland.Prescription of potentially inappropriate medication in older persons in Switzerland: does the dispensing channel make a difference?One-year adherence to oral antihyperglycemic medication and risk prediction of patient outcomes for adults with diabetes mellitus: An observational studyDays spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09).Cancer-related therapies at the end of life in hospitalized cancer patients from four Swiss cantons: SAKK 89/09.Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland.Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011-2015.Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context.The Patient Enrolled in a Managed Care Insurance Plan or the Physician Being Part of a Network: What Drives the Efficiency Gain?
P50
Q28542389-5A8BB100-D8CC-429C-821D-9469F9181D07Q30686074-05E691A6-2340-48A9-8646-2351818C0F23Q30828781-3842254C-41D2-4D73-AE09-FFD49F199B50Q30948835-4E8DFC8B-AF14-48F2-ACE3-391F13D35662Q33913975-5D825DB5-EA23-4115-958C-82DBC4AD3B52Q34353022-468A1495-5388-43F8-89AE-CB95BEB39E06Q34575547-E5361C1F-5EEE-41C4-94F2-18593781B596Q35565338-CABB9EBF-4D2A-4F72-93A0-4AD6D52FF11DQ37077938-26B11637-C5E8-4C34-B02A-8C7E7587CAE3Q38726493-ECC0ED6C-EDE6-47E4-84AC-CCBDAA951ADBQ44739734-F7BBCF21-75C2-44F9-9B72-C6CDC2DD4411Q47135721-61D46501-CD7C-4714-9D0E-3BD43747BBA3Q47595237-FCA6E7F0-03A3-4580-83B8-34BC14EC65E9Q51410130-6BADB503-F11A-4BB4-9440-27860D20E0EBQ87705312-AAEB3C9E-8B75-432E-8AC8-8BC72D1C0CCA
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-8287-290X
@en
name
Roland Rapold
@ast
Roland Rapold
@en
Roland Rapold
@es
Roland Rapold
@nl
type
label
Roland Rapold
@ast
Roland Rapold
@en
Roland Rapold
@es
Roland Rapold
@nl
prefLabel
Roland Rapold
@ast
Roland Rapold
@en
Roland Rapold
@es
Roland Rapold
@nl
P106
P21
P31
P496
0000-0001-8287-290X